ReviewThe Journal of biological chemistry2026
Control of the committed step in lipopolysaccharide biosynthesis.
Review in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lipopolysaccharide (LPS) is an essential component of the outer membrane of most Gram-negative bacteria. It maintains envelope integrity and forms a permeability barrier that protects cells from environmental stress, host defenses, and many antibiotics. LPS biosynthesis must be tightly controlled to ensure proper outer membrane assembly while preventing the toxic accumulation of intermediates. Central to this control is LpxC, a deacetylase that catalyzes the committed step in LPS biosynthesis and directs metabolic flux into the pathway. In Escherichia coli, LpxC abundance is primarily controlled by proteolysis mediated by the membrane-bound AAA + protease FtsH. This process is regulated by two essential membrane proteins, LapB and YejM. LapB acts as an adaptor that promotes LpxC degradation, whereas YejM functions as an antiadaptor that counteracts this activity. Through this regulatory network, signals from multiple stages of LPS biogenesis, along with inputs from other cell envelope biosynthetic pathways, are integrated to maintain LPS homeostasis. In addition to proteolytic control, new evidence suggests that LpxC enzymatic activity can also be modulated. Here, we summarize current understanding of the mechanisms governing LpxC regulation in E. coli and highlight unresolved questions. Further elucidation of these regulatory mechanisms may provide new opportunities for antibiotic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.